1. Home
  2. IKT vs EH Comparison

IKT vs EH Comparison

Compare IKT & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$1.97

Market Cap

274.9M

Sector

Health Care

ML Signal

N/A

Logo EHang Holdings Limited ADS

EH

EHang Holdings Limited ADS

N/A

Current Price

$4.20

Market Cap

314.0M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
IKT
EH
Founded
2008
2014
Country
United States
China
Employees
35
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
274.9M
314.0M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
IKT
EH
Price
$1.97
$4.20
Analyst Decision
Strong Buy
Buy
Analyst Count
9
11
Target Price
$6.00
★ $8.80
AVG Volume (30 Days)
424.9K
★ 588.0K
Earning Date
11-13-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 57.76
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.85
Revenue Next Year
$33.33
$77.51
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$3.95
52 Week High
$2.61
$19.01

Technical Indicators

Market Signals
Indicator
IKT
EH
Relative Strength Index (RSI) 34.43 37.56
Support Level $1.93 N/A
Resistance Level $2.13 $4.84
Average True Range (ATR) 0.10 0.16
MACD -0.01 0.00
Stochastic Oscillator 16.84 26.83

Price Performance

Historical Comparison
IKT
EH

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

About EH EHang Holdings Limited ADS

EHang Holdings Ltd is an urban air mobility (UAM) technology platform company focused on autonomous aerial vehicle technology and solutions. The company provides unmanned aerial vehicle (UAV) systems and solutions for air mobility, including passenger transportation and logistics, as well as smart city management and aerial media solutions. Its EH216-S passenger-carrying pilotless eVTOL aircraft has obtained a production certificate and standard airworthiness certificate from the Civil Aviation Administration of China (CAAC).

Share on Social Networks: